organization · Reporting owner

CORMORANT PRIVATE HEALTHCARE FUND I, LP

Disclosed activity across 6 companies

Tapewire entity: 145509
SEC CIK: 0001663781

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Apellis Pharmaceuticals, Inc.APLS · Entity 47322	10% owner	November 08, 2017	November 08, 2017
Axonics, Inc.AXNX · Entity 86004	10% owner	October 30, 2018	November 02, 2018
CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050	10% owner	July 18, 2018	July 20, 2018
Kezar Life Sciences, Inc.KZR · Entity 12111	10% owner	June 20, 2018	June 20, 2018
Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954	10% owner	May 23, 2018	May 23, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Apellis Pharmaceuticals, Inc.

Report date November 08, 2017 · Filed November 08, 2017

Jointly reported with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-11-08 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The convertible preferred stock is convertible at any time, at the holder's election, on a 2.133-for-one basis and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F2: Series D Convertible Preferred Stock reported herein represent (i) 1,573,936 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 442,014 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), and (iii) 82,631 shares held by a managed account (the "Account"). F4: Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Series E Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2017-11-08 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: The convertible preferred stock is convertible at any time, at the holder's election, on a 2.133-for-one basis and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F3: Series E Convertible Preferred Stock reported herein represent (i) 245,656 shares held by Fund I, (ii) 48,231 shares held by the Master Fund, and (iii) 10,029 shares held by the Account. F4: Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The convertible preferred stock is convertible at any time, at the holder's election, on a 2.133-for-one basis and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering.

F2: Series D Convertible Preferred Stock reported herein represent (i) 1,573,936 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 442,014 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), and (iii) 82,631 shares held by a managed account (the "Account").

F3: Series E Convertible Preferred Stock reported herein represent (i) 245,656 shares held by Fund I, (ii) 48,231 shares held by the Master Fund, and (iii) 10,029 shares held by the Account.

F4: Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Axonics, Inc.

Report date October 30, 2018 · Filed November 02, 2018 · Amendment

Jointly reported with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series B-2 Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-10-30 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance Not disclosed F1: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F2: Series B-2 Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 126,375 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), (ii) 450,000 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), and (iii) 23,624 shares held by a managed account (the "Account"). F4: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-10-30 · row 2 Amendment: may correct only part of an earlier disclosure. 1 source row Row 2 · Balance Not disclosed F1: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F3: Series C Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 96,985 shares held by the Master Fund, (ii) 435,788 shares held by Fund I, and (iii) 19,722 shares held by the Account. F4: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering.

F2: Series B-2 Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 126,375 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), (ii) 450,000 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), and (iii) 23,624 shares held by a managed account (the "Account").

F3: Series C Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 96,985 shares held by the Master Fund, (ii) 435,788 shares held by Fund I, and (iii) 19,722 shares held by the Account.

F4: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

CONSTELLATION PHARMACEUTICALS INC

Report date July 18, 2018 · Filed July 20, 2018 · Amendment

Jointly reported with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series F Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-07-18 · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · Balance Not disclosed F1: This Amendment is being filed to correct the number of shares of Common Stock underlying the convertible preferred stock previously reported in the initial Form 3. Such shares were previously reported without giving effect to a reverse stock split that became effective on July 6, 2018. F2: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F3: Series F Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 932,019 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 294,522 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and (iii) 45,144 shares held by a managed account (the "Account"). F4: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: This Amendment is being filed to correct the number of shares of Common Stock underlying the convertible preferred stock previously reported in the initial Form 3. Such shares were previously reported without giving effect to a reverse stock split that became effective on July 6, 2018.

F2: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering.

F3: Series F Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 932,019 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 294,522 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and (iii) 45,144 shares held by a managed account (the "Account").

Kezar Life Sciences, Inc.

Report date June 20, 2018 · Filed June 20, 2018

Jointly reported with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-06-20 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F2: Series A Redeemable Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 265,799 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and (ii) 49,689 shares held by a managed account (the "Account"). F4: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Series B redeemable Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-06-20 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: The convertible preferred stock is convertible at any time at the holder's election, without payment of additional consideration, and has no expiration date but is expected to convert automatically upon the closing of the Issuer's initial public offering. F3: Series B Redeemable Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 803,116 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 169,952 shares held by the Master Fund, and (iii) 34,353 shares held by the Account. F4: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F2: Series A Redeemable Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 265,799 shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and (ii) 49,689 shares held by a managed account (the "Account").

F3: Series B Redeemable Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 803,116 shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 169,952 shares held by the Master Fund, and (iii) 34,353 shares held by the Account.

Kiniksa Pharmaceuticals International, plc

Report date May 23, 2018 · Filed May 23, 2018

Jointly reported with Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series C Preferred SharesSEC Table II · derivative / convertible security	Direct	Not disclosed	Reported balance Holding disclosure · report date 2018-05-23 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: The Series C Preferred Shares are convertible at any time, at the holder's election, on a 1-for-2.73235 basis and have no expiration date. The Class C Preferred Shares are expected to convert automatically upon the closing of the Issuer's initial public offering. F2: The Series C Preferred Shares reported herein represent, on an as-converted basis, (i) 640,617 Common Shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 161,962 Common Shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), and (iii) 28,420 Common Shares held by a managed account (the "Account"). F3: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Shares are convertible at any time, at the holder's election, on a 1-for-2.73235 basis and have no expiration date. The Class C Preferred Shares are expected to convert automatically upon the closing of the Issuer's initial public offering.

F2: The Series C Preferred Shares reported herein represent, on an as-converted basis, (i) 640,617 Common Shares held by Cormorant Private Healthcare Fund I, LP ("Fund I"), (ii) 161,962 Common Shares held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), and (iii) 28,420 Common Shares held by a managed account (the "Account").

F3: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Fund I, the Master Fund and the Account. Bihua Chen serves as manager of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Atea Pharmaceuticals, Inc.

Report date November 03, 2020 · Filed November 05, 2020

Jointly reported with Cormorant Asset Management, LP, Chen Bihua, Cormorant Private Healthcare Fund II, LP, Cormorant Global Healthcare Master Fund, LP

Section 16 reporting ended · disclosed 2020-11-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	6,411,355	Reported balance After 2020-11-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-11-03 · Conversion · Acquired 6,411,355 · Balance 6,411,355 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3: Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-03 · Conversion · Disposed 1,000,000 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-03 · Conversion · Disposed 1,650,165 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-03 · Conversion · Disposed 2,631,580 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-03 · Conversion · Disposed 712,250 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F7: The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.
Series D-1 Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-11-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-03 · Conversion · Disposed 417,360 · Balance 0 F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F8: The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.

F2: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F3: Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account.

F4: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account.

F5: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account.

F6: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account.

F7: The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II.

F8: The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries D-1 Convertible Preferred Stock · Derivative	417,360	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 6 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 417,360 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F8 · ownership.nature: The Series D-1 Convertible Preferred Stock represented, on an as-converted basis, (i) 80,175 shares held by the Master Fund and (ii) 337,185 shares held by Fund II. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries D Convertible Preferred Stock · Derivative	712,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 5 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 712,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F7 · ownership.nature: The Series D Convertible Preferred Stock represented, on an as-converted basis, (i) 136,823 shares held by the Master Fund and (ii) 575,427 shares held by Fund II. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries C Convertible Preferred Stock · Derivative	2,631,580	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 4 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,631,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F6 · ownership.nature: The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 587,632 shares held by the Master Fund, (ii) 1,951,053 shares held by Fund I, and (iii) 92,895 shares held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries B Convertible Preferred Stock · Derivative	1,650,165	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 3 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,650,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F5 · ownership.nature: The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 396,040 shares held by the Master Fund, (ii) 1,155,115 shares held by Fund I, and (iii) 99,010 shares held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionSeries A Convertible Preferred Stock · Derivative	1,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · derivative · entry 2 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F4 · ownership.nature: The Series A Convertible Preferred Stock represented, on an as-converted basis, (i) 842,500 shares held by the Master Fund and (ii) 157,500 shares held by the Account. Read SEC document
November 03, 2020 Filed Nov 5, 2020 21:01 UTC	Atea Pharmaceuticals, Inc. AVIR · Entity 5580	ConversionCommon Stock	6,411,355	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-20-018747 · doc1.xml · nonDerivative · entry 1 Cormorant Asset Management, LP · CIK 0001583977 · Former 10% Owner Chen Bihua · CIK 0001599214 · Director · 10% owner Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner CORMORANT PRIVATE HEALTHCARE FUND I, LP · CIK 0001663781 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 6,411,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series A, Series B, Series C, Series D and Series D-1 Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering. F2 · ownership.nature: Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP ("Fund I"), Cormorant Private Healthcare Fund II, LP (the "Fund II"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, Fund II, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. F3 · ownership.nature: Represents (i) 2,043,170 shares of Common Stock held by the Master Fund, (ii) 3,106,168 shares of Common Stock held by Fund I, (iii) 912,612 shares of Common Stock held by Fund II, and (iv) 349,405 shares of Common Stock held by the Account. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.